Estónsko - estónčina - Ravimiamet

sandoz gmbh - liotüroniin - tablett - 25mcg 30tk

Európska únia - estónčina - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - solriamfetol vesinikkloriid - narcolepsy; sleep apnea, obstructive - psychoanaleptics, - sunosi on märgitud, et parandada ärkveloleku ja vähendada ülemäärane päevane unisus täiskasvanud patsientidel, kellel on narkolepsia (koos või ilma cataplexy). sunosi on märgitud, et parandada ärkveloleku ja vähendada ülemäärane päevane unisus (eds) täiskasvanud patsientidel, kellel on obstruktiivne uneapnoe hingamisteraapia (oua), kelle eds ei ole nõuetekohaselt töödeldud peamine osa ravi, nagu pidev positiivne hingamisteede rõhk (cpap).

Európska únia - estónčina - EMA (European Medicines Agency)

virbac s.a. - tulatromütsiin - antibakteriaalsed ained süsteemseks kasutamiseks - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. the product should only be used if pigs are expected to develop the disease within 2–3 days. lambad: nakkusliku pododermatiidi (suu mädanemine) varajase staadiumi ravi, mis on seotud virulentse dichelobacter nodosus'ega ja vajab süsteemset ravi.

Európska únia - estónčina - EMA (European Medicines Agency)

ceva santé animale - tulatromütsiin - antibakteriaalsed ained süsteemseks kasutamiseks - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. the product should only be used if pigs are expected to develop the disease within 2–3 days. lambad: nakkusliku pododermatiidi (suu mädanemine) varajase staadiumi ravi, mis on seotud virulentse dichelobacter nodosus'ega ja vajab süsteemset ravi.

Európska únia - estónčina - EMA (European Medicines Agency)

vetoquinol - tulatromütsiin - antibakteriaalsed ained süsteemseks kasutamiseks - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. the product should only be used if pigs are expected to develop the disease within 2–3 days. lambad: nakkusliku pododermatiidi (suu mädanemine) varajase staadiumi ravi, mis on seotud virulentse dichelobacter nodosus'ega ja vajab süsteemset ravi.

Európska únia - estónčina - EMA (European Medicines Agency)

elanco gmbh - tulatromütsiin - antibakteriaalsed ained süsteemseks kasutamiseks - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. the product should only be used if pigs are expected to develop the disease within 2–3 days. lambad: nakkusliku pododermatiidi (suu mädanemine) varajase staadiumi ravi, mis on seotud virulentse dichelobacter nodosus'ega ja vajab süsteemset ravi.

Európska únia - estónčina - EMA (European Medicines Agency)

vmd n.v. - tulatromütsiin - antibacterials for systemic use, macrolides - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. the product should only be used if pigs are expected to develop the disease within 2–3 days. lambad: nakkusliku pododermatiidi (suu mädanemine) varajase staadiumi ravi, mis on seotud virulentse dichelobacter nodosus'ega ja vajab süsteemset ravi.

Európska únia - estónčina - EMA (European Medicines Agency)

dechra regulatory b.v. - tulatromütsiin - antibakteriaalsed ained süsteemseks kasutamiseks - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. the product should only be used if pigs are expected to develop the disease within 2–3 days. lambad: nakkusliku pododermatiidi (suu mädanemine) varajase staadiumi ravi, mis on seotud virulentse dichelobacter nodosus'ega ja vajab süsteemset ravi.

Európska únia - estónčina - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Európska únia - estónčina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.